Serotonin (5-HT) in veins: Not all in vain

Journal of Pharmacology and Experimental Therapeutics

Volumn 323, Issue 2, 2007, Pages 415-421

  Linder, A Elizabeth ^a   Ni, Wei ^a   Diaz, Jessica L ^a   Szasz, Theodora ^a   Burnett, Robert ^a   Watts, Stephanie W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1,2,5,6 TETRAHYDRO 4 PYRIDYL)PYRROLO[3,2 B]PYRIDIN 5 ONE; BENSERAZIDE; CARBIDOPA; N (2 HYDROXYCYCLOPENTYL) 1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXAMIDE; N (3 DIMETHYLAMINO 2,3,4,9 TETRAHYDRO 1H CARBAZOL 6 YL) 4 FLUOROBENZAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN RECEPTOR AFFECTING AGENT; SUMATRIPTAN;

ARTERY CONSTRICTION; BLOOD VESSEL TONE; DEEP VEIN THROMBOSIS; DRUG INHIBITION; DRUG METABOLISM; DRUG RELEASE; DRUG STORAGE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONIN BLOOD LEVEL; SEROTONIN RELEASE; SEROTONIN UPTAKE; SEROTONINERGIC SYSTEM; VARICOSIS; VEIN; VENOCONSTRICTION; VENOUS CIRCULATION;

ANIMALS; AROMATIC-L-AMINO-ACID DECARBOXYLASES; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN; TRYPTOPHAN HYDROXYLASE; VARICOSE VEINS; VASOCONSTRICTION; VEINS; VENOUS THROMBOSIS;

EID: 35548996332     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.122630     Document Type: Review

References (39)

1. Banes AK and Watts SW (2001) Enhanced contraction to 5-hydroxytryptamine is not due to "unmasking" of 5-hydroxytryptamine(1b) receptors in the mesenteric artery of the deoxycorticosterone acetate-salt rat. Hypertension 38:891-895.
2. Banes AK and Watts SW (2003) Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol 3:12.
3. Bhattacharya A, Schenck KW, and Cohen ML (2003) Amplification of sumatriptaninduced contraction in rabbit saphenous vein but not in basilar artery. Am J Physiol Heart Circ Physiol 284:H719-H726.
4. Bhattacharya A, Schenck KW, Xu YC, Nissenbaum L, Galbreath E, and Cohen ML (2004) 5-Hydroxytryptamine1β receptor-mediated contraction of rabbit saphenous vein and basilar artery: role of vascular endothelium. J Pharmacol Exp Ther 309:825-832.
5. Bouchelet I, Case B, Olivier A, and Hamel E (2000) No contractile effect for 5-HT1D and 5-HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary artery. Br J Pharmacol 129:501-508.
6. Cohen ML and Schenck K (2000) Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5-HT(1F) receptor agonists and PGF(2alpha). Br J Pharmacol 131:562-568.
7. Cohen ML, Schenck KW, and Hemrick-Luecke SH (1999) 5- Hydroxytryptamine(1A) receptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein. J Pharmacol Exp Ther 290:1195-1201.
8. Ding XR, Stier CT Jr, and Itskovitz HD (1989) Serotonin and 5-hydroxytryptophan on blood pressure and renal blood flow in anesthetized rats. Am J Med Sci 297:290-293.
9. Eddahibi S, Guignabert C, Barlier-Mur AM, Dewachter L, Fadel E, Dartevelle P, Humbert M, Simonneau G, Hanoun N, Saurini F, et al. (2006) Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113:1857-1864.
10. Erspamer V and Vialli M (1937) Ricerche sul secreto delle cellule enterocromaffini. Boll Soc Med-Chir Pavia 51:357-363.
11. Froldi G, Nicoletti P, Caparrotta L, and Ragazzi E (2003) 5-HT receptors mediating contraction in the rat-tail artery. Adv Exp Med Biol 527:665-670.
12. Hellegouarch A, Baranes J, Clostre F, Drieu K, Braquet P, and DeFeudis FV (1985) Comparison of the contractile effects of an extract of Ginkgo biloba and some neurotransmitters on rabbit isolated vena cava. Gen Pharmacol 16:129-132.
13. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, and Humphrey PP (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203.
14. Jackson SP, Nesbitt WS, and Kulkarni S (2003) Signaling events underlying thrombus formation. J Thromb Haemost 1:1602-1612.
15. Kato S, Kumamoto H, Hirano M, Akiyama H, and Kaneko N (1999) Expression of 5-HT2A and 5-HT1B receptor mRNA in blood vessels. Mol Cell Biochem 199:57-61.
16. Kawano H, Tsuji H, Nishimura H, Kimura S, Yano S, Ukimura N, Kunieda Y, Yoshizumi M, Sugano T, Nakagawa K, et al. (2001) Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells. Blood 97:1697-1702.
17. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, and Eddahibi S (2003) Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:487-493.
18. McKune CM and Watts SW (2001) Characterization of the serotonin receptor mediating contraction in the mouse thoracic aorta and signal pathway coupling. J Pharmacol Exp Ther 297:88-95.
19. 3H]noradrenaline release and neurogenic contraction under identical conditions, to determine the prejunctional inhibitory effects of SKF 99101H and BRL 56905 in dog saphenous vein. Naunyn Schmiedebergs Arch Pharmacol 355:475-482.
20. Morecroft I, Dempsie Y, Bader M, Walther DJ, Kotnik K, Loughlin L, Nilsen M, and MacLean MR (2007) Effect of tryptophan hydroxylase 1 deficiency on the development of hypoxia-induced pulmonary hypertension. Hypertension 49:232-236.
21. Ni W, Thompson JM, Northcott CA, Lookingland K, and Watts SW (2004) The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol 43:770-781.
22. Ni W and Watts SW (2006) 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol 33:575-583.
23. Palmer DS, Aye MT, Ganz PR, Halpenny M, and Hashemi S (1994) Adenosine nucleotides and serotonin stimulate von Willebrand factor release from cultured human endothelial cells. Thromb Haemost 72:132-139.
24. Pang CC (2001) Autonomic control of the venous system in health and disease: effects of drugs. Pharmacol Ther 90:179-230.
25. Rappaport MM, Green AA, and Page IH (1948) Serum vasoconstrictor (serotonin). IV. Isolation and characterization. J Biol Chem 176:1243-1251.
26. Saxena PR and Ferrari MD (1992) From serotonin receptor classification to the antimigraine drug sumatriptan. Cephalalgia 12:187-196.
27. Thakali KM, Galligan JJ, Fink GD, and Watts SW (2007) Arterial and venous function in hypertension, in Comprehensive Hypertension (Hall JE and Granger JP eds) pp. 205-212, Mosby Elsevier, Philadelphia.
28. Trevethick MA, Feniuk W, and Humphrey PP (1984) 5-Hydroxytryptamine- induced relaxation of neonatal porcine vena cava in vitro. Life Sci 35:477-486.
29. Tsurumaki T, Nagai S, Bo X, Toyosato A, and Higuchi H (2006) Potentiation by neuropeptide Y of 5HT2A receptor-mediated contraction in porcine coronary artery. Eur J Pharmacol 544:111-117.
30. Ullmer C, Schmuck K, Kalkman HO, and Lubbert H (1995) Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 370:215-221.
31. Walther DJ and Bader M (2003) A unique central tryptophan hydroxylase isoform. Biochem Pharmacol 66:1673-1680.
32. Walther DJ, Peter JU, Winter S, Holtje M, Paulmann N, Grohmann M, Vowinckel J, Alamo-Bethencourt V, Wilhelm CS, Ahnert-Hilger G, et al. (2003) Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alphagranule release. Cell 115:851-862.
33. Watts SW (2000) 5-Hydroxytryptamine-induced potentiation of endothelin-1- and norepinephrine-induced contraction is mitogen-activated protein kinase pathway dependent. Hypertension 35:244-248.
34. Watts SW (2002) Serotonin-induced contraction in mesenteric resistance arteries: signaling and changes in deoxycorticosterone acetate-salt hypertension. Hypertension 39:825-829.
35. Watts SW (2005) 5-HT in systemic hypertension: foe, friend or fantasy? Clin Sci (Lond) 108:399-412.
36. Watts SW and Cohen ML (1999) Vascular 5-HT receptors: pharmacology and pathophysiology of 5-HT1B, 5-HT1D, 5-HT1F, 5-HT2B and 5-HT7 receptors. Neurotransmissions 15:3-15.
37. Watts SW and Thompson JM (2004) Characterization of the contractile 5-hydroxytryptamine receptor in the renal artery of the normotensive rat. J Pharmacol Exp Ther 309:165-172.
38. Whitaker-Azmitia PM (1999) The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology 21:2S-8S.
39. Yamamoto J, Ishii I, Okita N, Sasaki Y, Yamashita T, Matsuoka A, Muraki T, Giddings JC, Watanabe S, and Seki J (1997) The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Jpn J Physiol 47:431-441.